Bundle (CJC-1295 No Dac 2mg x5 + HEXARELIN 2mg x5)

This bundle contains five vials each of CJC-1295 NO-DAC (2mg) and Hexarelin (2mg), two separate synthetic peptides frequently studied together in growth hormone-related laboratory research. Each peptide is supplied individually and is intended for in vitro and in vivo (animal) laboratory research only.

CJC-1295 NO-DAC Research

CJC-1295 NO-DAC is a synthetic analog of growth hormone-releasing hormone (GHRH), studied for its interaction with the GHRH receptor. In an animal model study using GHRH-deficient mice, researchers examined CJC-1295's effects on growth hormone (GH) release patterns and growth-related metrics.¹

Hexarelin Research

Hexarelin is a synthetic analog of the gastrointestinal peptide ghrelin, studied for its interaction with the growth hormone secretagogue receptor (GHS-R), distinct from the GHRH receptor pathway studied with CJC-1295.² Animal model research has examined hexarelin's effects on cardiac cell signaling markers following induced myocardial injury.³

Combined Research Applications

Because CJC-1295 NO-DAC and Hexarelin act on different receptors involved in growth hormone signaling (GHRH receptor and GHS-R, respectively), researchers may study them together to examine combined effects on GH-related signaling pathways in animal models. Data specific to the combined use of these two peptides is limited, and any such research should be treated as exploratory.

Important Notice

CJC-1295 NO-DAC and Hexarelin are strictly for in vitro and in vivo (animal) laboratory research purposes only and are not intended for human or animal consumption. These findings do not establish safety, efficacy, or suitability for any human or animal application, and these products have not been evaluated by the FDA or any regulatory agency.

Product Information

This bundle includes 5 vials of CJC-1295 NO-DAC at 2mg per vial and 5 vials of Hexarelin at 2mg per vial, supplied as lyophilized powders for laboratory research use only.

References

1. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4.
2. Mao Y, Tokudome T, Kishimoto I. The cardiovascular action of hexarelin. J Geriatr Cardiol. 2014 Sep;11(3):253-258.
3. Zambelli V, Rizzi L, Delvecchio P, Bresciani E, et al. Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury. Drug Target Insights. 2021;15:26-33.